Company Filing History:
Years Active: 2011-2013
Title: Innovations by Qingfu Zeng in Lung Cancer Research
Introduction
Qingfu Zeng is a notable inventor based in Hamilton, MA, who has made significant contributions to the field of cancer research. He holds two patents that focus on the identification and treatment of non-small cell lung carcinoma (NSCLC). His work is crucial in advancing therapeutic strategies for this challenging disease.
Latest Patents
Zeng's latest patents revolve around the identification of NSCLC tumors that express platelet-derived growth factor receptor alpha (PDGFR-α). The inventions disclose a previously unidentified subset of mammalian NSCLC tumors where PDGFR-α is expressed and drives the disease. These patents provide methods for identifying NSCLC tumors likely to respond to PDGFR-α-inhibiting therapies. Additionally, they offer techniques for inhibiting the progression of PDGFR-α-expressing NSCLC tumors and for determining the efficacy of compounds in this context.
Career Highlights
Qingfu Zeng is associated with Cell Signaling Technology, Inc., where he continues to contribute to innovative research in cancer biology. His work has implications for improving patient outcomes through targeted therapies.
Collaborations
Zeng collaborates with notable colleagues such as Klarisa Rikova and Roberto Polakiewicz, enhancing the research efforts in his field.
Conclusion
Qingfu Zeng's innovative patents and research efforts are paving the way for advancements in the treatment of non-small cell lung carcinoma. His contributions are vital for the ongoing fight against cancer and improving therapeutic options for patients.